QTTB

Q32 Bio Inc. (QTTB) | Rumor.io

Q32 Bio

QTTB

Attention (50-day avg)0%

Attention rank (50-day avg)#1,879

Bullish sentiment (50-day avg)52%

Price to earnings ratio2.79

Market capitalization274.8M

Earnings per share3.14

Dividend yield (TTM)—

Revenue (annual)53.7M

Net income (annual)29.8M

Social

What share of all stock conversation is about QTTB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Jul 15

Q32 Bio Inc. (QTTB) has priced a $200M public offering of common stock and pre-funded warrants at $18.25 per share.
The offering includes 6.03M shares and 4.93M pre-funded warrants, with the proceeds to support clinical development of bempikibart.
Q32 Bio's stock price has declined 26.7% since the offering news, with the current price at $16.25.

Generated by AI

Sentiment

Of the messages about QTTB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	72.73% +27.57	52.8% -28.22
Bearish	—	0%	27.27% -27.57	47.2% +28.22

Bullish· Jul 13

The company's stock price could reach $100 by the end of the week due to the company's positive performance.
The Oppenheimer analyst maintains a strong outlook for the company, raising the price target from $20 to $40 and maintaining an "Outperform" rating.
The stock's price action is expected to continue, with a strong support zone in the mid-teens and near-term resistance in the $20-$23 area.

Bearish· Jul 14

Q32 Bio Inc. may be experiencing a correction after its recent announcement of a $200M placement, which could lead to a price drop in the teens.
The company's stock may be vulnerable to a significant decline, with some analysts predicting it could reach $15-$16.
Q32 Bio Inc.'s recent price pop may be short-lived, as the stock has a history of fading after initial gains, potentially leading to a significant decline.

Generated by AI

Topics

Of the messages about QTTB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	49.33%	49.33%	75%	12.08%
Technical Analysis	0%	0%	0%	6.87%
Analysts	50.67%	50.67%	25%	39.79%
Macro	0%	0%	0%	41.22%
Controversies	0%	0%	0%	0.03%
Earnings	0%	0%	0%	0.01%

Announcements· Jul 13

Q32 Bio Inc. (QTTB) announces positive 36-week topline results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata, with 40% of evaluable patients reaching SALT-20, meaning at least 80% scalp hair.
The company plans to advance the antibody into a registration-directed program during the first half of 2027, with key data including a 35.3% average reduction in hair-loss severity and a clean safety profile.
Q32 Bio's stock price surged after the announcement, with a nearly 100% increase in a single trading day, and the company's market cap reaching approximately $340 million.

Technical Analysis· Dec 1

Key resistance for $QTTB is at $4.50, breaking through could lead to a strong push to $5.00, with potential for further gains up to $25.00.
Buyers are accumulating shares above $4.00, suggesting a potential bounce or breakout in the near future.
The Relative Strength Index (RSI) for $QTTB is already oversold, indicating a possible reversal or bounce in the stock's price.

Generated by AI

Community

Of the messages about QTTB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	5.66%	64.79%	26.27%
Newcomers	100%	94.34%	35.21%	73.73%

Jul 15

Q32 Bio Inc. ($QTTB) has priced a $200M public offering of common stock and pre-funded warrants at $18.25 per share, with 6.03M shares and 4.93M pre-funded warrants issued.
The company will use the funds to support the clinical development of bempikibart, and the underwriters have an option for an additional 1.64M shares.
The stock has pulled back after the announcement, but is expected to have a near-term negative market impact, and some analysts believe the company's 2x increase in float could lead to volatility.

Generated by AI

News

Why is Q32 Bio stock surging today?

1d agoInvesting.com

Clear Street initiates Q32 Bio stock with buy rating on drug potential

1d agoInvesting.com

Jefferies initiates Q32 Bio stock coverage with buy rating on alopecia potential

2d agoInvesting.com

Q32 Bio: Durable Hair Regrowth Remains The Goal (NASDAQ:QTTB)

QTTB stock outlook: bempikibart may deliver lasting alopecia areata hair regrowth; financing reduces near-term risk.

3d agoSeeking Alpha

Cantor Fitzgerald reiterates Q32 Bio stock rating on hair loss data

13d agoInvesting.com

Q32 Bio at cantor healthcare conference: bempikibart gains ground

20d agoInvesting.com

Also Discussed

Investors talking about QTTB also mention

#	Name	Attention
1	Advanced Biomed Inc.ADVB	0%0
2	AMC Robotics CorporationAMCI	0%0
3	Nektar TherapeuticsNKTR	0.08%+0.03
4	SMX (Security Matters) Public Limited CompanySMX	0%+0
5	TNL Mediagene Ordinary SharesTNMG	0%new
6	Shattuck Labs, Inc.STTK	0%new
7	GCL Global Holdings LtdGCL	0%0
8	Actuate Therapeutics, Inc.ACTU	0%0
9	Coincheck Group N.V.CNCK	0%new
10	MeiraGTx Holdings plcMGTX	0%new

Q32 Bio Inc.

Healthcare
Biotechnology

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions. Q32 Bio’s pipeline includes bempikibart, an antibody-based candidate designed to regulate immune signaling in dermatology and related autoimmune settings, as well as research efforts in complement-pathway biology for tissue-targeted immune control. The company’s work is positioned within the broader biopharmaceutical sector, where precision immunology and biologics play an important role in addressing chronic diseases with limited treatment options. Based in Waltham, Massachusetts, Q32 Bio continues to operate as a research-focused company advancing specialized therapies from clinical development programs.

Website

Location

830 Winter Street

Waltham, MA, 02451

United States

Social

What share of all stock conversation is about QTTB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Jul 15

Q32 Bio Inc. (QTTB) has priced a $200M public offering of common stock and pre-funded warrants at $18.25 per share.
The offering includes 6.03M shares and 4.93M pre-funded warrants, with the proceeds to support clinical development of bempikibart.
Q32 Bio's stock price has declined 26.7% since the offering news, with the current price at $16.25.

Generated by AI

Sentiment

Of the messages about QTTB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	72.73% +27.57	52.8% -28.22
Bearish	—	0%	27.27% -27.57	47.2% +28.22

Bullish· Jul 13

The company's stock price could reach $100 by the end of the week due to the company's positive performance.
The Oppenheimer analyst maintains a strong outlook for the company, raising the price target from $20 to $40 and maintaining an "Outperform" rating.
The stock's price action is expected to continue, with a strong support zone in the mid-teens and near-term resistance in the $20-$23 area.

Bearish· Jul 14

Q32 Bio Inc. may be experiencing a correction after its recent announcement of a $200M placement, which could lead to a price drop in the teens.
The company's stock may be vulnerable to a significant decline, with some analysts predicting it could reach $15-$16.
Q32 Bio Inc.'s recent price pop may be short-lived, as the stock has a history of fading after initial gains, potentially leading to a significant decline.

Generated by AI

Topics

Of the messages about QTTB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	49.33%	49.33%	75%	12.08%
Technical Analysis	0%	0%	0%	6.87%
Analysts	50.67%	50.67%	25%	39.79%
Macro	0%	0%	0%	41.22%
Controversies	0%	0%	0%	0.03%
Earnings	0%	0%	0%	0.01%

Announcements· Jul 13

Q32 Bio Inc. (QTTB) announces positive 36-week topline results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata, with 40% of evaluable patients reaching SALT-20, meaning at least 80% scalp hair.
The company plans to advance the antibody into a registration-directed program during the first half of 2027, with key data including a 35.3% average reduction in hair-loss severity and a clean safety profile.
Q32 Bio's stock price surged after the announcement, with a nearly 100% increase in a single trading day, and the company's market cap reaching approximately $340 million.

Technical Analysis· Dec 1

Key resistance for $QTTB is at $4.50, breaking through could lead to a strong push to $5.00, with potential for further gains up to $25.00.
Buyers are accumulating shares above $4.00, suggesting a potential bounce or breakout in the near future.
The Relative Strength Index (RSI) for $QTTB is already oversold, indicating a possible reversal or bounce in the stock's price.

Generated by AI

Community

Of the messages about QTTB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	5.66%	64.79%	26.27%
Newcomers	100%	94.34%	35.21%	73.73%

Jul 15

Q32 Bio Inc. ($QTTB) has priced a $200M public offering of common stock and pre-funded warrants at $18.25 per share, with 6.03M shares and 4.93M pre-funded warrants issued.
The company will use the funds to support the clinical development of bempikibart, and the underwriters have an option for an additional 1.64M shares.
The stock has pulled back after the announcement, but is expected to have a near-term negative market impact, and some analysts believe the company's 2x increase in float could lead to volatility.

Generated by AI

Q32 Bio

Social

Jul 15

Bullish· Jul 13

Bearish· Jul 14

Announcements· Jul 13

Technical Analysis· Dec 1

Jul 15

Why is Q32 Bio stock surging today?

Clear Street initiates Q32 Bio stock with buy rating on drug potential

Jefferies initiates Q32 Bio stock coverage with buy rating on alopecia potential

Q32 Bio: Durable Hair Regrowth Remains The Goal (NASDAQ:QTTB)

Cantor Fitzgerald reiterates Q32 Bio stock rating on hair loss data

Q32 Bio at cantor healthcare conference: bempikibart gains ground

Also Discussed

Q32 Bio Inc.

Company Information

Location

Why is Q32 Bio stock surging today?

Clear Street initiates Q32 Bio stock with buy rating on drug potential

Jefferies initiates Q32 Bio stock coverage with buy rating on alopecia potential

Q32 Bio: Durable Hair Regrowth Remains The Goal (NASDAQ:QTTB)

Cantor Fitzgerald reiterates Q32 Bio stock rating on hair loss data

Q32 Bio at cantor healthcare conference: bempikibart gains ground

Also Discussed

Social

Jul 15

Bullish· Jul 13

Bearish· Jul 14

Announcements· Jul 13

Technical Analysis· Dec 1

Jul 15